Abstract:
Objective: To elicit the pathogenetic response of Buxus sempervirens Linn. in homoeopathic potencies
on healthy human volunteers.
Methodology: Buxus sempervirens drug was proved by the Central Council for Research in
Homoeopathy (CCRH) through randomized, double-blind, placebo-controlled method. The proving
was conducted at three centres during 2007-08. The drug was proved in 6 & 30 centesimal potencies
on 57 apparently healthy volunteers, declared eligible after their pre-trial medical examination by the
medical specialists and routine laboratory investigations. In its first phase of proving, volunteers were
given 56 doses of placebo divided in 4 doses per day for 14 days. In the next two phases, 56 doses
of pre-selected potencies or placebo as per the randomization were consumed in divided doses same
as in first phase. The symptoms generated during the trial period were noted down by the volunteers
and elaborated by the Proving Masters. The generated data of the drug from all three centres was
compiled at the proving-cum-data processing cell at CCRH headquarters after de-coding.
Observations: Out of 40 provers who were on actual drug trial, only 23 manifested symptoms. The
drug was able to generate symptoms in both the potencies to every part of the body.
Conclusion: The pathogenetic response elicited during the proving trial, expands the scope of use
of the drug Buxus sempervirens and will benefit the research scholars and clinicians. The generated
symptoms of this drug will carry more value when verified clinically.
